Lobbying return by Pender & Associates Ltd
HealthIntended results
Attendance at an event presenting the Medicines for Ireland Manifesto 2019
Politician · TD · 34th Dáil
Dessie Ellis
- Constituency / panel
- Dublin North-West
- Membership
- 2024-11-29 → current
- Committees
- 2 current — Joint Committee on Key Issues Affecting the Traveller Community; Select Committee on Key Issues Affecting the Traveller Community
- 0
- Declared items
- 0
- CRO-matched interests
- 0
- Awards to declared companies
- 612
- Lobbying returns
- 8
- SIPO donation records
- 87%
- Vote participation
Reports for 2017–2025 (party) and 2020–2022 (members)
369 of 422 divisions
Check it yourself
SIPO donation reports 8
- Political Party Donation Statements 2025 (PDF) (opens in a new tab)
- Political Party Donation Statements 2024 (PDF) (opens in a new tab)
- Political Party Donation Statements 2023 (PDF) (opens in a new tab)
- Donations to Political Parties 2022 (PDF) (opens in a new tab)
- Donations to Political Parties 2021 (PDF) (opens in a new tab)
- Donations to Political Parties 2020 (PDF) (opens in a new tab)
- Donations to Political Parties 2019 (PDF) (opens in a new tab)
- Donations to Political Parties 2018 (PDF) (opens in a new tab)
Lobbying returns
Returns filed on the Register of Lobbying, newest first, with the policy area and intended results as the lobbyist published them.
Filters
Clear allAreaAll 43Health 10Housing 4Justice and Equality 4Budgetary matters 3Children and Youth Affairs 3Agriculture 2Community 2Foreign Affairs 2Local Government 2Trade 2Economic Development and Industry 1Education and Training 1Employment 1Energy and Natural Resources 1Finance 1Social Protection 1Sports and Recreation 1Taxation 1Transport 1
Lobbying return by Abbvie Limited
HealthIntended results
Invitation to AbbVie corporate responsibility event
Derived link · Matched by exact company name
Published name "Abbvie Limited" equals CRO name "ABBVIE LIMITED" (CRO 510846) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.
Lobbying return by Irish Cancer Society
HealthIntended results
Abolition of the inpatient charge::Reduction in the drugs payment scheme threshold::Abolition of the prescription charge on a phased basis::Reduction of car parking charges at hospitals::Full implementation of the National Cancer Strategy::Secure additional funding for the Irish…
Derived link · Matched by exact company name
Published name "Irish Cancer Society" equals CRO name "IRISH CANCER SOCIETY" (CRO 20868) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.
Lobbying return by Multiple Sclerosis Ireland
HealthIntended results
To secure additional annual statutory funding of €600,000 to open our care centre 50 weeks per year.
Lobbying return by Multiple Sclerosis Ireland
HealthIntended results
To make our elected representatives aware that access to medications is an issue for people living with multiple sclerosis.
Lobbying return by Multiple Sclerosis Ireland
HealthIntended results
To secure additional annual statutory funding of €600,000 to open our care centre 50 weeks per year.
Lobbying return by Multiple Sclerosis Ireland
HealthIntended results
To secure additional annual statutory funding of €600,000 to open our care centre 50 weeks per year.
Lobbying return by Multiple Sclerosis Ireland
HealthIntended results
To make our elected representatives aware that access to medications is an issue for people living with multiple sclerosis.
Lobbying return by Ana Liffey Drug Project
HealthIntended results
A health-led drugs policy
Derived link · Matched by exact company name
Published name "Ana Liffey Drug Project" equals CRO name "ANA LIFFEY DRUG PROJECT" (CRO 109034) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.
Lobbying return by Comhlámh
HealthIntended results
Transparency around the cost of research and development (R&D), marketing, production and distribution of new medicines so as to facilitate governments in negotiating a fair price for the public health system.